Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.

Cluster analysis European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30) Health-related quality of life (HRQoL) Patient reported outcomes Randomized clinical trials (RCTs)

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
07 2022
Historique:
received: 01 02 2022
revised: 18 03 2022
accepted: 30 03 2022
pubmed: 16 5 2022
medline: 29 6 2022
entrez: 15 5 2022
Statut: ppublish

Résumé

The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) measures 15 health-related quality of life (HRQoL) scales relevant to the disease and treatment of patients with cancer. A study by Martinelli (2011) demonstrated that these scales could be grouped into three main clusters: physical, psychological and gastrointestinal. This study aims to validate Martinelli's findings in an independent dataset and evaluate whether these clusters are consistent across cancer types and patient characteristics. Pre-defined criteria for successful validation were three main clusters should emerge with a minimum R-squared value of 0.51 using pooled baseline-data. A cluster analysis was performed on the 15 QLQ-C30 HRQoL-scales in the overall dataset, as well as by cancer type and selected patient characteristics to examine the robustness of the results. The dataset consisted of 20,066 patients pooled across 17 cancer types. Overall, three main clusters were identified (R This study successfully validated prior findings by Martinelli (2011): the QLQ-C30 scales are interrelated and can be grouped into three main clusters. Knowing how these multidimensional HRQoL scales are related to each other can help clinicians and patients with cancer in managing symptom burden, guide policymakers in defining social-support plans and inform selection of HRQoL scales in future clinical trials.

Identifiants

pubmed: 35569438
pii: S0959-8049(22)00187-3
doi: 10.1016/j.ejca.2022.03.039
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Abigirl Machingura (A)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Electronic address: abigirl.machingura@eortc.be.

Mekdes Taye (M)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Jammbe Musoro (J)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Jolie Ringash (J)

Princess Margaret Cancer Centre and the University of Toronto, The Canadian Cancer Trials Group (CCTG), Canada.

Madeline Pe (M)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Corneel Coens (C)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Francesca Martinelli (F)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Dongsheng Tu (D)

Departments of Public Health Sciences, And Mathematics & Statistics, Queen's University, Canada.

Ethan Basch (E)

Lineberger Comprehensive Cancer Center, UNC, USA.

Yvonne Brandberg (Y)

Department of Oncology-Pathology, Karolinska Institutet, Sweden.

Mogens Grønvold (M)

Department of Public Health, University of Copenhagen, Denmark.

Alexander Eggermont (A)

Princess Máxima Center, Utrecht and University Medical Center Utrecht, the Netherlands; Comprehensive Cancer Center Munich, Germany.

Fatima Cardoso (F)

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.

Jan Van Meerbeeck (J)

Antwerp University and Antwerp University Hospital, Edegem, Belgium.

Winette T A van der Graaf (WTA)

Department of Medical Oncology, Netherlands Cancer Institute Amsterdam, the Netherlands; Department of Medical Oncology Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.

Martin Taphoorn (M)

Leiden University Medical Center, Leiden and Haaglanden Medical Center, The Hague, the Netherlands.

Jaap C Reijneveld (JC)

Department of Neurology, Amsterdam University Medical Centre, Amsterdam, Netherlands & SEIN, Heemstede, Netherlands.

Riccardo Soffietti (R)

Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science University Hospital, Turin, Italy.

Jeff Sloan (J)

Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.

Galina Velikova (G)

Leeds Institute of Medical Research at St James's University, University of Leeds and Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, UK.

Henning Flechtner (H)

Department of Child and Adolescent Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.

Andrew Bottomley (A)

European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH